Home > Boards > US Listed > Medical - Healthcare > Pfenex Inc. (PFNX)

And here's the reason

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Paullee Member Profile
 
Followed By 18
Posts 2,913
Boards Moderated 0
Alias Born 11/25/03
160x600 placeholder
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/11/2021 3:25:04 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 12/9/2020 5:03:13 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 10/9/2020 2:54:29 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 10/9/2020 11:55:46 AM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 10/9/2020 9:16:52 AM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 10/9/2020 6:31:14 AM
Termination of Registration of a Class of Security Under Section 12(b) (15-12b) Edgar (US Regulatory) - 10/5/2020 5:20:11 PM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 10/5/2020 6:03:56 AM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 10/2/2020 4:29:26 PM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 10/2/2020 4:27:51 PM
Notification Filed by National Security Exchange to Report the Removal From Listing and Registration of Matured, Redeemed or ... Edgar (US Regulatory) - 10/1/2020 3:43:19 PM
Post-effective Amendment to an S-8 Filing (s-8 Pos) Edgar (US Regulatory) - 10/1/2020 2:23:44 PM
Post-effective Amendment to Registration Statement (pos Am) Edgar (US Regulatory) - 10/1/2020 2:18:35 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 10/1/2020 8:40:39 AM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 9/30/2020 4:23:03 PM
Amended Tender Offer Statement by Third Party (sc To-t/a) Edgar (US Regulatory) - 9/30/2020 8:07:08 AM
Amended Statement of Ownership: Solicitation (sc 14d9/a) Edgar (US Regulatory) - 9/30/2020 8:06:32 AM
Ligand Announces Expiration of Tender Offer for Shares of Pfenex Inc. Business Wire - 9/30/2020 8:00:00 AM
Confidential Treatment Order (ct Order) Edgar (US Regulatory) - 9/22/2020 12:18:14 PM
Amended Statement of Ownership: Solicitation (sc 14d9/a) Edgar (US Regulatory) - 9/18/2020 5:07:49 PM
Paullee   Wednesday, 12/18/19 08:12:01 AM
Re: None
Post # of 59 
And here's the reason
Pfenex Earns $15 Million Development Milestone Under its Development and License Agreement With Jazz Pharmaceuticals
GlobeNewswire GlobeNewswire•December 18, 2019
SAN DIEGO, Dec. 18, 2019 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX) today announced that it has earned a $15 million development milestone under its development and license agreement with Jazz Pharmaceuticals plc. The milestone is associated with process development activities for PF745, a long-acting Erwinia asparaginase.

“We are very pleased with the rapid progression of the PF745 program and we believe the Jazz collaboration, overall, further validates the versatility of our proprietary protein expression platform and the quality of our development capabilities,” said Eef Schimmelpennink, Chief Executive Officer of Pfenex. “Additionally, we are excited about Jazz’s recent announcement that the lead product in our partnership, PF743 (JZP-458), is expected to begin recruiting patients into the pivotal Phase 2/3 clinical study as early as this month.”

Under the terms of the development and license agreement, Pfenex is eligible to receive an aggregate total of up to $224.5 million in development and sales milestones, of which $162.5 million is still eligible to be received by Pfenex, including up to $3.5 million for development milestones, $34 million in regulatory milestones and $125 million in sales milestones. Pfenex may also be eligible to receive tiered royalties based on worldwide sales of any products resulting from the collaboration.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences